Pulmozyme DNase to thin lung secretions data

Phase III results in 968 patients showed that the company's recombinant human enzyme reduced the age-adjusted risk of respiratory tract infections by 28 percent over 24 weeks in the group taking 2.5 mg once a day (p = 0.04), and by 37 percent in those taking it twice daily (p=0.01).

The data, published in the New England Journal of Medicine, had been included in the South San Francisco company's filing for FDA approval. ...